We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Expands Personalized Care Access Via Telehealth Platform
Read MoreHide Full Article
Key Takeaways
HIMS integrates telehealth, EMRs and AI to deliver personalized, subscription-based healthcare.
Hims & Hers plans to enter Canada in 2026, pairing generic treatments with digital care programs.
A new CTO appointment highlights HIMS' focus on scaling AI-driven care personalization.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , operates on a digital-first, consumer-centric healthcare model that integrates telehealth technology, personalized treatment and a vertically connected care ecosystem. Its platform enables customers to access licensed healthcare professionals for consultations and prescriptions, supported by an integrated electronic medical record (EMR) system, cloud pharmacy fulfillment and data-driven personalization tools. This structure allows Hims & Hers to offer care for a wide range of conditions — spanning sexual health, dermatology, mental health and weight management — through a seamless digital experience that extends from diagnosis to delivery.
HIMS’ model emphasizes scalability and accessibility, using proprietary algorithms and a distributed provider network to deliver care efficiently and at scale. Most offerings are sold on a subscription basis, creating predictable recurring revenue while ensuring continuity of treatment. The integration of its affiliated pharmacies and in-house compounding and manufacturing facilities strengthens its supply chain and supports cost-effective personalized care delivery. Hims & Hers’ platform design also facilitates international expansion, as seen in its entry into Europe through the ZAVA acquisition and its planned 2026 expansion into Canada, where it will pair affordable generic treatments — such as semaglutide for weight loss — with personalized digital care programs.
Central to Hims & Hers’ evolution is its use of AI and technology to enhance personalization and care quality. The appointment of a new chief technology officer (CTO) in 2025 underscores the company’s commitment to developing an AI-powered platform capable of integrating diagnosis, treatment and delivery into a unified experience. This digital and telehealth foundation enables Hims & Hers to redefine traditional healthcare delivery, offering accessible, affordable and individualized treatment at scale.
GDRX & LFMD’s Telehealth-Integrated Digital Care Models
GoodRx Holdings, Inc. (GDRX - Free Report) operates a digital healthcare platform focused on affordability and accessibility. GoodRx combines prescription price transparency, telehealth and manufacturer savings programs through its website and app, enabling users to compare real-time medication prices and access low-cost care. Its GoodRx Care service integrates virtual consultations with prescription fulfillment, creating a comprehensive, consumer-first telehealth ecosystem that simplifies how patients access and manage treatment.
LifeMD, Inc. (LFMD - Free Report) runs a direct-to-patient telehealth platform integrating virtual primary care, behavioral health and lifestyle treatments. LifeMD’s digital system combines a national medical network, in-house pharmacy, diagnostics and EMRs to deliver seamless end-to-end care. LifeMD’s subscription-based model — anchored by programs like GLP-1 weight management — uses AI-driven benefit verification and personalized virtual care to make healthcare more accessible and efficient.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 140.6% year to date, outperforming the industry’s growth of 35.5%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 4.9X is lower than the industry’s average of 6.2X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 122.2% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #4 (Sell).
Image: Bigstock
Hims & Hers Expands Personalized Care Access Via Telehealth Platform
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , operates on a digital-first, consumer-centric healthcare model that integrates telehealth technology, personalized treatment and a vertically connected care ecosystem. Its platform enables customers to access licensed healthcare professionals for consultations and prescriptions, supported by an integrated electronic medical record (EMR) system, cloud pharmacy fulfillment and data-driven personalization tools. This structure allows Hims & Hers to offer care for a wide range of conditions — spanning sexual health, dermatology, mental health and weight management — through a seamless digital experience that extends from diagnosis to delivery.
HIMS’ model emphasizes scalability and accessibility, using proprietary algorithms and a distributed provider network to deliver care efficiently and at scale. Most offerings are sold on a subscription basis, creating predictable recurring revenue while ensuring continuity of treatment. The integration of its affiliated pharmacies and in-house compounding and manufacturing facilities strengthens its supply chain and supports cost-effective personalized care delivery. Hims & Hers’ platform design also facilitates international expansion, as seen in its entry into Europe through the ZAVA acquisition and its planned 2026 expansion into Canada, where it will pair affordable generic treatments — such as semaglutide for weight loss — with personalized digital care programs.
Central to Hims & Hers’ evolution is its use of AI and technology to enhance personalization and care quality. The appointment of a new chief technology officer (CTO) in 2025 underscores the company’s commitment to developing an AI-powered platform capable of integrating diagnosis, treatment and delivery into a unified experience. This digital and telehealth foundation enables Hims & Hers to redefine traditional healthcare delivery, offering accessible, affordable and individualized treatment at scale.
GDRX & LFMD’s Telehealth-Integrated Digital Care Models
GoodRx Holdings, Inc. (GDRX - Free Report) operates a digital healthcare platform focused on affordability and accessibility. GoodRx combines prescription price transparency, telehealth and manufacturer savings programs through its website and app, enabling users to compare real-time medication prices and access low-cost care. Its GoodRx Care service integrates virtual consultations with prescription fulfillment, creating a comprehensive, consumer-first telehealth ecosystem that simplifies how patients access and manage treatment.
LifeMD, Inc. (LFMD - Free Report) runs a direct-to-patient telehealth platform integrating virtual primary care, behavioral health and lifestyle treatments. LifeMD’s digital system combines a national medical network, in-house pharmacy, diagnostics and EMRs to deliver seamless end-to-end care. LifeMD’s subscription-based model — anchored by programs like GLP-1 weight management — uses AI-driven benefit verification and personalized virtual care to make healthcare more accessible and efficient.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 140.6% year to date, outperforming the industry’s growth of 35.5%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 4.9X is lower than the industry’s average of 6.2X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 122.2% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.